Dear Clients & Visitors, In conjunction of the Labour Day, CytoMed Therapeutics (Malaysia) Sdn Bhd's office will be closed on the following date: Date : 1st May 2024 (Wednesday) We will resume operation as usual on the following date: Date : 2rd May 2024 (Thursday) 💪 💪 Wishing you a happy and restful Labour Day, where you can take a break from your hard work and enjoy some well-deserved relaxation. Cheers to all out there! May this Labour Day be a celebration of your contribution to society. Happy Labour Day!!!
CytoMed Therapeutics Limited
Biotechnology Research
Harnessing proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers.
About us
Incorporated in 2018, CytoMed was spun off from the Agency for Science, Technology and Research (A*STAR), Singapore’s national research and development agency in the public sector. CytoMed is a biopharmaceutical company focused on harnessing its licensed proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of novel technologies has been inspired by the clinical success of existing CAR-T in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into treatment of solid tumors.
- Website
-
https://w2.cytomed.sg
External link for CytoMed Therapeutics Limited
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Singapore
- Type
- Public Company
- Founded
- 2018
Locations
-
Primary
Get directions
1 Commonwealth Ln, #08-22
Singapore, 149544, SG
Employees at CytoMed Therapeutics Limited
-
Siti Nurusaadah Hamzah
Project Administrator at CytoMed Therapeutics (Malaysia) Sdn Bhd. (Subsidiary of CytoMed Therapeutics Ltd)
-
Wee Kiat Tan, Ph.D
Company Builder| Cell Therapy| CTGP| GMP | Nasdaq |
-
Mark L.
Experienced Corporate Director & Business Executive
-
Lucas Luk Tien Wee
MB BCH BAO (Ireland) MRCOG (UK) Fertility Specialist (Adv Dip, Fellowship UKSH)
Updates
-
"Wee Kiat Tan, Ph.D., co-CEO, Director and COO of CytoMed Therapeutics Limited, will be a featured speaker at the Cell & Gene Therapy and Cryogenics Logistics World Asia 2024." #celltherapy #gammaTCell #WellnessJourney , etc. https://lnkd.in/gYfWBi9R
Recognised as APAC's premier CGT conference, Cell & Gene Therapy and Cryogenic Logistics World Asia 2024 promises to be at the centre of industry development by offering invaluable knowledge exchange and partnership opportunities! Discover more in our brand-new brochure: https://lnkd.in/gRvaRBjv We've put together a series of insightful sessions led by renowned industry leaders such as: Xiaoping Cao, PhD MBA, SVP, Head of Technical Operations at JW Therapeutics 药明巨诺, China Wee Kiat Tan, Ph.D, Director and Coo of CytoMed Therapeutics Limited, Singapore Udaykumar Kolkundkar, Senior Vice President - Technical Operations at Stempeutics Research Private Limited, India Jia Min Loo, Senior Director - Discovery at Nuevocor, Singapore Ryuichi Morishita, Professor of Department of Clinical Gene Therapy, CoMIT at Osaka University, Japan With over 600+ attendees from 250+ organisations, this is your ultimate opportunity to connect the most sought-after decision-makers from the industry and drive transformative change. Don't miss this once-in-a-lifetime opportunity! Save $200 and secure your spot today: - Singapore Company: https://lnkd.in/gjfmrJg5 - Non-Singapore Company: https://lnkd.in/gPDE5B5e Interested in sponsoring? Download our sponsorship prospectus: https://lnkd.in/gRvaRBjv
-
-
“CytoMed Therapeutics is mentioned as an active player in induced pluripotent stem cells in Bioinformant’s Report as below. https://lnkd.in/g2kbSFq
-
Dr. Raghav Sundar (right), Dr. Anand Jeyasekharan (centre) and Dr Joan Choo (left), at the AACR Annual Meeting 2024 San Diego, presenting on a phase I trial to evaluate allogeneic NKG2DL-targeting chimeric antigen receptor-grafted γδ T cells in subjects with advanced solid tumors or hematological malignancies (the ANGELICA Trial). #ClinicalTrial #tumors #hematology #PhaseI
-
-
Dr Wee Kiat Tan, Ph.D, at CGT Asia 2024 (cont.) #cancerimmunotherapy #offtheshelf #Immunotherapy #cellandgenetherapy
-
-
Dr.Wee Kiat Tan, Ph.D at CGT Asia 2024 in Shanghai, giving his presentation on Next Generation "Off-the-shelf" Cell-based Cancer Immunotherapeutics #cancerimmunotherapy #offtheshelf #Immunotherapy #cellandgenetherapy
-
-
Stay tuned tomorrow as Dr. Tan Wee Kiat, delivers a keynote speech on Next Generation "off-the-shelf" Cell-based Immunotherapeutics at CGT Asia 2024 in Shanghai. #celltherapy #immunotherapeutics #offtheshelf
纳斯达克上市公司新加坡 CytoMed Therapeutics 联席首席执行官将出席CGT Asia并带来话题演讲
mp.weixin.qq.com
-
Join us at CGT Asia 2024 in Shanghai, on Apr 2 & 3 to find out more about Next Generation "off-the-shelf" Cell-based Immunotherapeutics, with our co-CEO & COO, Dr. Wee Kiat Tan, Ph.D #celltherapy #immunotherapeutics #offtheshelf
纳斯达克上市公司新加坡 CytoMed Therapeutics 联席首席执行官将出席CGT Asia并带来话题演讲
mp.weixin.qq.com
-
We're excited to announce that our co-CEO & COO, Dr. Wee Kiat Tan, Ph.D, will be attending the CGT Asia 2024 in Shanghai, to deliver a keynote speech on Next Generation "off-the-shelf" Cell-based Immunotherapeutics. #celltherapy #immunotherapeutics #offtheshelf
纳斯达克上市公司新加坡 CytoMed Therapeutics 联席首席执行官将出席CGT Asia并带来话题演讲
mp.weixin.qq.com